国内首个AD血液检测产品落地乐城

Core Insights - The Elecsys pTau181 blood test for Alzheimer's disease (AD) has received approval from the Hainan Provincial Drug Administration, marking a significant advancement in the diagnosis and treatment of AD in China [2] - This blood test is the first of its kind to receive dual certification from both the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) and the FDA, enabling its use in primary healthcare settings for assessing AD and other cognitive decline causes [2][3] - The introduction of this blood test is expected to facilitate early detection and intervention for millions of individuals with cognitive impairments, transitioning from passive response to proactive management of Alzheimer's disease [3] Technology and Performance - The Elecsys pTau181 test utilizes electrochemiluminescence technology to ensure high sensitivity and stability, specifically targeting phosphorylated Tau protein at the 181 site, which is indicative of Alzheimer's pathology [3] - A global clinical study has shown that the test has a negative predictive value of 93.8%, allowing healthcare providers to confidently rule out Alzheimer's disease in patients with negative test results [3] Market Impact - The Elecsys pTau181 blood test is being implemented in the Hainan Boao Research Hospital, leveraging the "first trial" policy advantages to provide convenient and reliable early screening services for cognitive impairment in China [3] - This development is positioned to support the aging population in China by enhancing health management for the elderly and addressing the challenges posed by an increasing number of cognitive impairment cases [3]